Selective α7 nAChR Ligands for Non-Narcotic Cough Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing nicotinic compounds used to treat CNS disorders and inflammation have undesirable side effects due to activity at cardiovascular and skeletal muscle sites, necessitating the development of compounds that selectively target α7 nAChRs without these side effects.
Innovation Solution
Development of compounds of general formula (I) and their pharmaceutically acceptable salts, which act as selective α7 nAChR agonists, providing a novel, non-narcotic approach for treating conditions like acute and chronic cough, and demonstrating anti-inflammatory effects in pulmonary disease models.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If known nicotinic compounds are used to treat CNS disorders and inflammation, then therapeutic effect is achieved, but undesirable side effects occur due to activity at cardiovascular and skeletal muscle sites
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures (formula I) that possess selective affinity for α7 nAChRs. The compounds contain specific substituents (R1-R6 groups) that create localized chemical properties enabling selective binding to α7 receptors while avoiding other nicotinic receptor subtypes, thereby achieving therapeutic effect at the target site without harmful side effects at cardiovascular and muscle sites
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters (substituents R1-R6, their positions, and chemical groups) to optimize the compound's pharmacological profile. By adjusting these structural parameters, the compounds achieve high selectivity for α7 nAChRs with reduced affinity for other receptor subtypes, transforming the pharmacological parameters to eliminate side effects while maintaining therapeutic efficacy
2Reliability
If compounds with high affinity for α7 nAChRs are developed, then selective therapeutic activity is achieved, but structural complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the molecular structure into distinct functional segments: a core scaffold (azabicyclo non-3-ene) and variable substituent groups (R1-R6). This modular segmentation allows systematic variation of specific regions to optimize α7 nAChR affinity while maintaining overall structural manageability. The core structure provides the basic binding framework while substitutable groups fine-tune selectivity without requiring complete redesign of the entire molecule
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively inhibit cough responses and reduce inflammation without significant side effects, offering a safer therapeutic option for CNS disorders and inflammatory conditions.
Implementation Method 1
the compounds of general formula (I) of the invention advantageously affect the central nervous system without inducing potentially undesirable side effects of nicotinic receptor subtypes
Data Source
AI summary
Compounds of formula (I) or a pharmaceutically acceptable salt thereof and pharmaceutical compositions thereof are provided. Additionally, methods to manufacture the compounds are described. The compounds are nicotinic acetylcholine receptor (nAChR) ligands, which are useful for the suppression and/or prevention of coughing.